- Home
- DEO vs ALNY Comparison
DEO vs ALNY Comparison
Compare DEO & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DEO | ALNY |
|---|---|---|
| Founded | 1886 | 2002 |
| Country | United Kingdom | United States |
| Employees | 29860 | 2500 |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.4B | 40.8B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | DEO | ALNY |
|---|---|---|
| Price | $79.16 | $304.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 28 |
| Target Price | $109.00 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 1.6M | 961.8K |
| Earning Date | 02-25-2026 | 04-30-2026 |
| Dividend Yield | ★ 4.08% | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | N/A | ★ 2.33 |
| Revenue | N/A | ★ $1,037,418,000.00 |
| Revenue This Year | $2.65 | $52.67 |
| Revenue Next Year | N/A | $31.48 |
| P/E Ratio | ★ $90.04 | $134.23 |
| Revenue Growth | N/A | ★ 22.88 |
| 52 Week Low | $72.45 | $246.00 |
| 52 Week High | $116.69 | $495.55 |
Technical Indicators
Market Signals| Indicator | DEO | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 49.77 | 41.46 |
| Support Level | $72.73 | N/A |
| Resistance Level | $91.26 | $337.10 |
| Average True Range (ATR) | 1.82 | 10.14 |
| MACD | 0.55 | -1.72 |
| Stochastic Oscillator | 64.45 | 9.99 |
Price Performance
Historical ComparisonAbout DEO Diageo plc
Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.